Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Mobilization of Stem Cells with AMD3100 in Non-Hodgkin’s Lymphoma Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 78
Pharmaceutical / Industry
AMD3100-3101
NCT00103610
2.
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 to 65
Other
03-0349
NCT00241358
3.
Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 to 80
Pharmaceutical / Industry
MOZO00207
NCT00694590
4.
AMD3100 + G-CSF Mobilization for Autologous Transplant for Patients With Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Approved-not yet active
18 to 75
Other
08-X177
NCT00733824
5.
AMD3100 With Mitoxantrone, Etoposide and Cytarabine in Relapsed or Refractory AML
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
07-0227
NCT00512252
6.
AMD3100 With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed HSC Collection/Attempts
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 78
Pharmaceutical / Industry
AMD3100-2112
NCT00396331
7.
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM), Who Have Failed Previous Mobilization
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Active
18 to 78
Pharmaceutical / Industry
AMD3100-EU23
EudraCT number: 2006-00424729, NCT00665314
8.
Safety Study of AMD3100 With G-CSF to Increase Peripheral Blood Stem Cells
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Supportive care
Active
18 to 70
Pharmaceutical / Industry
H-18743
NCT00291811
9.
Long-Term Follow Up Study for AMD3100 Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Active
18 to 78
Other
2006-0665
NCT00476294
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute